A Study of Pembrolizumab in Combination With Epacadostat in Women With Recurrent/Metastatic Endometrial Carcinoma

NCT03310567 · clinicaltrials.gov ↗

PHASE2

Phase

WITHDRAWN

Status

OTHER

Sponsor class

Stopped Sponsors pulled out of the study

Conditions

Recurrent/ Metastatic Endometrial Carcinoma

Interventions

DRUG: Epacadostat + pembrolizumab

Sponsor

Fox Chase Cancer Center